Cargando…

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study

Management and treatment of terminal metastatic castration-resistant prostate cancer (mCRPC) remains heavily debated. We sought to investigate the efficacy of programmed cell death 1 (PD-1) inhibitor plus anlotinib as a potential solution for terminal mCRPC and further evaluate the association of ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Xin-Xing, Dong, Yan-Hao, Zhu, Han-Jing, Fei, Xiao-Chen, Gong, Yi-Ming, Xia, Bin-Bin, Wu, Fan, Wang, Jia-Yi, Liu, Jia-Zhou, Fan, Lian-Cheng, Wang, Yan-Qing, Dong, Liang, Zhu, Yin-Jie, Pan, Jia-Hua, Dong, Bai-Jun, Xue, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Invited Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069691/ https://www.ncbi.nlm.nih.gov/pubmed/36537376 http://dx.doi.org/10.4103/aja2022102

Ejemplares similares

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
por: Yu, Evan Y, et al.
Publicado: (2014)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
por: Zhou, Zi‐Chao, et al.
Publicado: (2022)

Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study
por: Zou, Hanhui, et al.
Publicado: (2022)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
por: Huang, Jia-Yi, et al.
Publicado: (2023)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
por: Luo, Jun
Publicado: (2016)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
por: Song, Yan, et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
por: Zhou, Lingxiao, et al.
Publicado: (2023)

Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report
por: Zhang, Zibo, et al.
Publicado: (2022)

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma
por: Zhu, Xiao-Dong, et al.
Publicado: (2022)

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Wu, Jia-Yi, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
por: Yuan, Jing, et al.
Publicado: (2022)

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer
por: Zheng, Wubin, et al.
Publicado: (2022)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
por: Liu, Qingyan, et al.
Publicado: (2023)

Peripheral naïve CD8(+) T cells as a predictive biomarker of response to lenvatinib plus an anti‐PD‐1 antibody in advanced hepatocellular carcinoma: a biomarker study
por: Huang, Cheng, et al.
Publicado: (2022)

Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report
por: Zhang, Zibo, et al.
Publicado: (2022)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
por: Liu, Shaochuan, et al.
Publicado: (2020)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti–PD–1 antibody
por: Xu, Bin, et al.
Publicado: (2022)

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
por: Xu, Qin, et al.
Publicado: (2022)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer
por: Hao, Yan-Yan, et al.
Publicado: (2021)

Anlotinib dramatically improved pulmonary hypertension and hypoxia caused by Pulmonary Tumor Thrombotic Microangiopathy (PTTM) associated with gastric carcinoma: a case report
por: Wang, Yang, et al.
Publicado: (2023)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
por: Liu, Jiayong, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rdhkke1m770v1435dfje5kqpng